Correspondence on “Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial” by Molto et al

With great interest, we read the results of the tight control in spondyloarthritis (TICOSPA) study1 in which a tight-control/treat-to-target strategy (T2T) was compared with usual care in patients with axial spondyloarthritis (axSpA). In this study which was the first ever to use a T2T strategy in axSpA, a main outcome parameter was used that had never been used before: the percentage of patients with a ≥30% improvement on the ‘Assessment of Spondyloarthritis’ (ASAS) Health Index (ASAS-HI), and other conventional efficacy outcomes were also recorded.2 As recently explained, one important reasons to use the ASAS HI in TICOSPA as primary endpoint was to avoid circular reasoning, for example, using the same items for inclusion and outcome.3

The aim of this correspondence is not to discuss the strategy used in the trial since this has been done in a recent editorial but to discuss the use of this outcome parameter which represents a tool that has been developed over many years with >2000 patients and a major input from patients. This is also documented by the fact that 5 items out of the 17 in the ASAS HI were proposed by patients with ankylosing spondylitis (AS) and they are not part of any other tool that has been used in axSpA.4

The ASAS HI is a disease-specific health index designed to assess global functioning and health in patients with axSpA that had originally been started to overcome the problem to define disease severity because this domain contains many different aspects of the disease: disease activity, damage, reduced mobility, reduced physical function, reduced social participation. The impact of function and activity on the disease has recently been intensively reviewed.5 Thus, it comes close to the meaning of impact of the disease. The impact of the disease might be related to quality of life, but is even a bit broader than the subjective experience of those problems. This broader concept is included in the International Classification of Functioning, Disability and Health (ICF) which has been published by the world health organisation (WHO) in 2001. The ICF represents an universally accepted model that classifies and describes functioning, disability and health in individuals with a wide spectrum of diseases or conditions in a systematic way.

The term ‘functioning’ in the context of the ICF is equated more with ‘health’ than ‘function’ as the latter term is limited to physical function and ignores the complexity of global functioning. The ASAS HI covers areas of physical, emotional and social functioning based on categories summarised in the ASAS/WHO ICF core set for AS.6 Within the Comprehensive ICF Core Set, 80 categories were selected which describe the typical spectrum of problems related to the functioning of patients with AS in a multidisciplinary assessment, 66 items relate to functioning and 14 to environmental factors which have recently been looked at in more detail.4

The ASAS HI is a 17-item instrument covering sum scores ranging from 0 (good health) to 17 (poor health). Each item consists of one question that the patient needs to respond to with either ‘I agree’ (score 1), ‘I do not agree’ (score 0). An improvement ≥3 from baseline in ASAS HI represents a clinically meaningful change and attaining a ‘good health status’ is defined by this should be ≥3.0. ASAS HI scoring points,7 this should be taken into account.

In summary, we do think that the ASAS HI is a useful outcome instrument in clinical trials which, in addition to disease activity and function, is able to convince us about an improvement that made a real difference for patients.

Uta Kiltz ●, Juergen Braun ●
Rheumazentrum Ruhrgebiet, Ruhr Universität Bochum, Herne, Germany

Correspondence to Dr Juergen Braun, Rheumazentrum Ruhrgebiet, Herne 44649, Germany; juergen.braun@elisabethgruppe.de

Contributors Both authors have equally contributed.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

UK and JB contributed equally.

To cite Kiltz U, Braun J. Ann Rheum Dis Epub ahead of print: [please include Day Month Year], doi:10.1136/annrheumdis-2021-221423

Received 6 September 2021
Accepted 7 September 2021
Ann Rheum Dis 2021:0:1. doi:10.1136/annrheumdis-2021-221423

ORCID iDs
Uta Kiltz http://orcid.org/0000-0001-5668-4497
Juergen Braun http://orcid.org/0000-0002-9156-5095

REFERENCES
6 Kiltz Uetal. Development of an environmental contextual factor item set relevant to global functioning and health in axial spondyloarthritis patients. Rheumatology 2021.